AU2018253961B2 - Coversin variants lacking C5 binding - Google Patents

Coversin variants lacking C5 binding Download PDF

Info

Publication number
AU2018253961B2
AU2018253961B2 AU2018253961A AU2018253961A AU2018253961B2 AU 2018253961 B2 AU2018253961 B2 AU 2018253961B2 AU 2018253961 A AU2018253961 A AU 2018253961A AU 2018253961 A AU2018253961 A AU 2018253961A AU 2018253961 B2 AU2018253961 B2 AU 2018253961B2
Authority
AU
Australia
Prior art keywords
seq
ala
replaced
coversin
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018253961A
Other languages
English (en)
Other versions
AU2018253961A1 (en
Inventor
Miles Andrew Nunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of AU2018253961A1 publication Critical patent/AU2018253961A1/en
Application granted granted Critical
Publication of AU2018253961B2 publication Critical patent/AU2018253961B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018253961A 2017-04-21 2018-04-20 Coversin variants lacking C5 binding Active AU2018253961B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
PCT/EP2018/060240 WO2018193121A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding

Publications (2)

Publication Number Publication Date
AU2018253961A1 AU2018253961A1 (en) 2019-10-31
AU2018253961B2 true AU2018253961B2 (en) 2022-06-02

Family

ID=58795719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018253961A Active AU2018253961B2 (en) 2017-04-21 2018-04-20 Coversin variants lacking C5 binding

Country Status (12)

Country Link
US (2) US11214602B2 (enExample)
EP (1) EP3612207B1 (enExample)
JP (1) JP7183180B2 (enExample)
KR (1) KR102630702B1 (enExample)
CN (1) CN110799207B (enExample)
AU (1) AU2018253961B2 (enExample)
CA (1) CA3060336A1 (enExample)
ES (1) ES2980279T3 (enExample)
GB (1) GB201706406D0 (enExample)
IL (1) IL269856B2 (enExample)
PL (1) PL3612207T3 (enExample)
WO (1) WO2018193121A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077709A1 (en) * 2000-03-21 2003-04-24 Masazumi Kamohara Novel leukotriene B4 receptor
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MANS B J ET AL, "Function, mechanism and evolution of the moubatin-clade of soft tick lipocalins", INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD, GB, vol. 38, no. 9, pages 841 - 852 *

Also Published As

Publication number Publication date
IL269856B2 (en) 2024-09-01
CN110799207A (zh) 2020-02-14
EP3612207C0 (en) 2024-04-10
PL3612207T3 (pl) 2024-09-23
GB201706406D0 (en) 2017-06-07
US11214602B2 (en) 2022-01-04
EP3612207B1 (en) 2024-04-10
EP3612207A1 (en) 2020-02-26
WO2018193121A1 (en) 2018-10-25
CN110799207B (zh) 2024-05-03
IL269856A (en) 2019-11-28
AU2018253961A1 (en) 2019-10-31
IL269856B1 (en) 2024-05-01
US20230002456A1 (en) 2023-01-05
JP2020517260A (ja) 2020-06-18
KR20190141163A (ko) 2019-12-23
US20200385434A1 (en) 2020-12-10
ES2980279T3 (es) 2024-09-30
JP7183180B2 (ja) 2022-12-05
KR102630702B1 (ko) 2024-01-29
CA3060336A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
US11214602B2 (en) Coversin variants lacking C5 binding
JP6621741B2 (ja) Ｃｔｌａ−４に対する親和性が改善したｃｄ８６バリアント
EP3047024B1 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
KR20140054009A (ko) 릴랙신 융합 폴리펩타이드 및 그의 용도
AU2009211257A1 (en) Treatment of diseases and conditions mediated by eicosanoids
KR20140129163A (ko) 인간 보체 c5에 결합하는 폴리펩티드
JP7209637B2 (ja) 自己免疫性水疱症の治療のためのコバーシン
FR2972006A1 (fr) Nouveaux fragments d'il-33 superactifs et leurs utilisations
DK2393831T3 (en) MODIFIED OMCI AS COMPLEMENT INHIBITOR
JP2025511929A (ja) 長時間作用型顆粒球マクロファージコロニー刺激因子
BR112019019819A2 (pt) polipeptídeo de ligação a il-1r-i
EP3419994B1 (en) Peptide inhibitors of calcium channels
JP2020525033A (ja) アセチルコリン受容体結合ペプチド
WO2013156771A1 (en) Anti-atherogenic peptides
JP5312025B2 (ja) Ｉｌ−３２モジュレーター
CN102028935A (zh) 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
CN111440227B (zh) 一种抑制肿瘤转移及骨肿瘤的多肽及其应用
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
CN103059110A (zh) 白念珠菌细胞凋亡促进因子基因及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)